Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX

Vanguard Group Inc. reduced its position in shares of Arcellx, Inc. (NASDAQ:ACLX) by 1.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,907,087 shares of the company’s stock after selling 37,798 shares during the period. Vanguard Group Inc. owned 7.04% of Arcellx worth $320,772,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CWM LLC lifted its holdings in Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 251 shares during the period. State of Wyoming bought a new stake in shares of Arcellx during the 2nd quarter valued at $28,000. PNC Financial Services Group Inc. grew its position in shares of Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock worth $49,000 after buying an additional 486 shares during the period. Abich Financial Wealth Management LLC bought a new position in shares of Arcellx in the 3rd quarter worth about $62,000. Finally, Principal Financial Group Inc. purchased a new position in Arcellx during the 3rd quarter valued at about $215,000. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Analyst Upgrades and Downgrades

ACLX has been the topic of a number of analyst reports. Evercore set a $115.00 price target on shares of Arcellx in a research note on Monday. UBS Group lowered Arcellx from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $100.00 to $115.00 in a report on Tuesday. Wells Fargo & Company downgraded Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price target on the stock. in a report on Monday, February 23rd. Canaccord Genuity Group set a $115.00 target price on shares of Arcellx in a report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $111.87.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 7,437 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total transaction of $487,197.87. Following the sale, the insider directly owned 29,631 shares of the company’s stock, valued at $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rami Elghandour sold 89,916 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the completion of the sale, the insider owned 276,051 shares in the company, valued at approximately $31,447,729.92. The trade was a 24.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 109,366 shares of company stock valued at $11,526,708. 8.35% of the stock is owned by insiders.

Arcellx Price Performance

Shares of ACLX opened at $113.79 on Friday. The firm has a market cap of $6.58 billion, a P/E ratio of -28.95 and a beta of 0.36. The company has a 50 day simple moving average of $71.81 and a two-hundred day simple moving average of $76.22. Arcellx, Inc. has a 1 year low of $47.86 and a 1 year high of $114.26.

Trending Headlines about Arcellx

Here are the key news stories impacting Arcellx this week:

• Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
• Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Market commentary pieces (example: “Is It Too Late To Consider Arcellx…”) are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
• Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
• Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to “Hold” — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

Arcellx Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.